evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Live zoster vaccine vs placebo

Cumulative incidence of herpes zoster, 3.1 years · healthy older adults aged ≥ 60 years

Live zoster vaccine probably leads to lower cumulative incidence of herpes zoster, 3.1 years compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Adverse effects of any severity (systemic symptoms) · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any systemic symptomClinical… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Dropouts ‐ did not receive second dose Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher dropouts ‐ did not receive second doseClinical or laboratory criteria compared with placebo (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).

1 finding from 1 review